Public signal · 1-minute delayed

Signal brief

Source-backed market context you can read and share without an account.

CORTBullishCorporate Developmentsnews

High materiality10/10

Corcept Therapeutics Experimental Lead Drug Cuts Death Risk By 35% In Advanced Ovarian Cancer Patients, Stock Jumps

Jan 22, 2026, 11:31 AM EST1 sourcesAI-analyzed

Why it may matterVerify against the original reporting

The robust trial results suggest increased revenues from relacorilant, offsetting prior FDA concerns, similar to stocks experiencing rebounds after favorable clinical trial outcomes.

AI summary

What happened, with direct paths to the underlying reporting

Corcept Therapeutics' shares surged after the Phase 3 ROSELLA trial showed relacorilant significantly improved overall survival in ovarian cancer patients. With a 35% reduction in death risk and a well-tolerated safety profile, investor sentiment has boosted CORT's stock, despite an earlier FDA setback for hypertension treatment.

CORT shares rose 19.14% following positive Phase 3 trial results.
Relacorilant plus nab-paclitaxel improved overall survival by 35%.
Median overall survival was 16.0 months versus 11.9 months.
Treatment was well-tolerated, showing no increased safety burden.
FDA issued a CRL for hypertensive use of relacorilant in December.

How to read this signal

Transparent limits for an AI-generated research aid

StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.

Corcept Therapeutics Experimental Lead Drug Cuts Death Risk By 35% In Advanced Ovarian Cancer Patients, Stock Jumps

Corcept Therapeutics Stock Surges After FDA Approves Ovarian Cancer Drug

Corcept Therapeutics Stock Plunges As Court Clears Teva Generic

Corcept Therapeutics Under Investigation for Securities Fraud After FDA Warnings Cause Share Price to Plummet

Corcept shares tumble after FDA letter reveals warnings before drug rejection